| Literature DB >> 30170613 |
Kenneth Ssekatawa1,2, Dennis K Byarugaba3, Edward Wampande3, Francis Ejobi3.
Abstract
OBJECTIVE: In this systematic review, we present the molecular epidemiology and knowledge gaps of the carbapenem resistance in East Africa as well as the future probable research interventions that can be used to address the emergence of carbapenem resistance in the region.Entities:
Keywords: Carbapenem resistance; East Africa; Molecular epidemiology
Mesh:
Substances:
Year: 2018 PMID: 30170613 PMCID: PMC6119249 DOI: 10.1186/s13104-018-3738-2
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Fig. 1Selection process of research articles for inclusion in this systematic review
Review of East Africa based carbapenem resistance studies
| Location | Number of isolates | CR isolates | CR prevalence (%) | Carbapenemase genes | Organism | Period | Methods used | Refs |
|---|---|---|---|---|---|---|---|---|
| Kenya | 416 | 57 | 13.7 | VIM-2 |
| Jan 2006–Jun 2007 | PCR, PFGE and sequencing | [ |
| Kenya | > 100 | 7 | – | NDM-1 |
| 2007–2009 | PCR, PFGE and sequencing | [ |
| Kenya | – | 16 | – | NDM-1 |
| Jan 2009–Aug 2010 | PCR, PFGE, Sequencing and MBL Etest strips | [ |
| Kenya | 190 | 44 | 23.2 | – |
| 2002–2013 | Disk diffusion | [ |
| Kenya | 195 | 25 | 12.8 | NDM-1 like |
| 1994–2017 | WGS | [ |
| Kenya | 17/219 | 1/219 or 1/17 | 0.5/5.9 | – |
| 2010 | Disk diffusion | [ |
| Kenya | 42 | 3 | 7 | – |
| – | Disk diffusion | [ |
| Uganda | 196 | 44 | 22.4 | OXA-48, IMP, KPC and NDM-1 | Jan 2013–Mar 2014 | PCR. Disk diffusion and Modified Hodge test | [ | |
| Uganda | 658 | 68 | 10.3 | VIM and OXA-48 | Sept 2013–Jun 2014 | PCR and disk diffusion | [ | |
| Uganda | 869 (clinical) | 10 | 1.2 (10/869) | IMP-like, VIM-like, SPM-like and NDM-1-like | Feb 2007–Sep 2009 | PCR | [ | |
| 9 | 1.1 (9/869) | OXA-23,24, 58 like and VIM-like | ||||||
| 80 (environmental) | 15 | 18.8 (15/80) | IMP-like, VIM-like, SPM-like and NDM-1-like | |||||
| 6 | 7.5 (6/80) | OXA-23,24, 58 like and VIM-like | ||||||
| Uganda | 736 (clinical) | 3 | 0.41 (3/736) | – | Sept 2012–Oct 2013 | Rep-PCR and disk diffusion | [ | |
| 1 | 0.14 (1/736) | – | ||||||
| 100 (environmental) | 7 | 7 (7/100) | – | |||||
| 6 | 6 (6/100) | – | ||||||
| Tanzania | 90 | 8 | 8.9 | VIM-2 |
| May 2010–Jul 2011 | Sequencing, PGFE and Disc diffusing | [ |
| Tanzania | 227 | 80 | 35 | VIM-, IMP-, NDM-KPC, OXA48 | 2007–2012 | PCR and disk diffusion | [ | |
| Rwanda | 55/154 | 5 in 154 or 5/55 | 2.9/8 | – |
| Jul–Dec 2013 | Disk diffusion | [ |
| Ethiopia | 33 | 4 | 12.1 | – | Jan–Mar 2014 | Disc diffusion and | [ | |
| Ethiopia | 267 | 5 | 1.87 | – |
| Dec 2012 | [ | |
| DRC | 104/643 | 1 in 643 or 1/104 | 0.2/0.96 | – | Sept 2012–Aug 2013 | Disk diffusion | [ |
Sample wise distribution of CR bacteria isolates
| Country | Sample source | CR prevalence | Species | Refs |
|---|---|---|---|---|
| Kenya | Urine | 3/57 = 5% (urine) |
| [ |
| Kenya | Blood (190) | 44/190 = 23.2% |
| [ |
| Kenya | Respiratory tract specimens | 10/16 = 55.6% (respiratory) |
| [ |
| Kenya | Blood (195) | 25/195 = 12.8% |
| [ |
| Kenya | Urine (121) | 1/17 = 5.9% |
| [ |
| Uganda | Urine | 23% | [ | |
| Uganda | Blood (51), cerebral spinal fluid (49), Tracheal aspirates (163), Ear swabs (197), Sputum (204), Urine catheters (98) and Pus (107) | 3/42 = 7.14% (wound/Pus) |
| [ |
| 4/29 = 13.8% (Tracheal) |
| |||
| Tanzania | Blood and pus | 5/90 = 5.6% Wound/Pus |
| [ |
| Tanzania | Pus (112), urine (56), blood (55), aspirate (3), and sputum (1). | 22/56 = 39.29% (Urine) |
| [ |
| Ethiopia | Urine (24) | 4/24 = 17% (urine) | [ | |
| Ethiopia | Feces (267) | 5/267 = 2% (feces) |
| [ |
| DRC | Urine (104) | 1/104 = 0.96% (urine) | [ |